Do you want to read an article? Please log in or register.
Triglyceride-Rich Lipoprotein Cholesterol, Small Dense LDL Cholesterol, and Incident Cardiovascular Disease
Cardiovascular Risk and Diseases
RECOMMENDED
Related content
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Remnant-Like Particle Cholesterol, Low-Density Lipoprotein Triglycerides, and Incident Cardiovascular Disease
J Am Coll Cardiol.
Saeed A, Feofanova EV, Yu B, Sun W, Virani SS, Nambi V, Coresh J, Guild CS, Boerwinkle E, Ballantyne CM, Hoogeveen RC
doi: 10.1016/j.jacc.2018.04.050.
COMMENTED
Lipid-Lowering Drugs
Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting
Eur Heart J.
Verbeek R, Hoogeveen RM, Langsted A, Stiekema LCA, Verweij SL, Hovingh GK, Wareham NJ, Khaw KT, Boekholdt SM, Nordestgaard BG, Stroes ESG
doi: 10.1093/eurheartj/ehy334.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
LDL-Cholesterol Lowering for the Primary Prevention of Cardiovascular Disease Among Men with Primary Elevations of LDL-Cholesterol Levels of 190 mg/dL or Above: Analyses from the WOSCOPS 5-year Randomised Trial and 20-year Observational Follow-Up
Circulation.
Vallejo-Vaz AJ, Robertson M, Catapano AL, Watts GF, Kastelein JJ, Packard CJ, Ford I, Ray KK
doi: 10.1161/
Lipid-Lowering Drugs
Association of Triglyceride-Lowering LPL Variants and LDL-C-Lowering LDLR Variants With Risk of Coronary Heart Disease
JAMA.
Ference BA, Kastelein JJP, Ray KK, Ginsberg HN, Chapman MJ, Packard CJ, Laufs U, Oliver-Williams C, Wood AM, Butterworth AS, Di Angelantonio E, Danesh J, Nicholls SJ, Bhatt DL, Sabatine MS, Catapano AL
doi: 10.1001/jama.2018.20045.
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Low-Density Lipoprotein Cholesterol and Drug Treatment to Lower Atherosclerotic Cardiovascular Disease Risk: Where Do We Stand?
JAMA Cardiol.
Lloyd-Jones DM
doi: 10.1001/
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Low-density lipoprotein cholesterol treatment and outcomes in patients with type 2 diabetes and established cardiovascular disease: Insights from TECOS
Am Heart J.
De Ferrari GM, Stevens SR, Ambrosio G, Leonardi S, Armstrong PW, Green JB, Wamil M, Holman RR, Peterson ED, TECOS Study Group.
doi: 10.1016/j.ahj.2019.11.005.
REOMMENDED
Cardiovascular Risk and Diseases
Associations of Dietary Cholesterol or Egg Consumption With Incident Cardiovascular Disease and Mortality
JAMA.
Zhong VW, Van Horn L, Cornelis MC, Wilkins JT, Ning H, Carnethon MR, Greenland P, Mentz RJ, Tucker KL, Zhao L, Norwood AF, Lloyd-Jones DM, Allen NB
doi: 10.1001/jama.2019.1572.
RECOMMENDED
Lipid-Lowering Drugs
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial
★ 3
Recommended by
Prof. Dr Isabella Sudano, Faculty Member
JAMA.
Goldberg AC, Leiter LA, Stroes ESG, Baum SJ, Hanselman JC, Bloedon LT, Lalwani ND, Patel PM, Zhao X, Duell PB
doi: 10.1001/jama.2019.16585.
RECOMMENDED
Cardiovascular Risk and DiseasesLipid-Lowering Drugs
Triglyceride and Triglyceride/ HDL (High Density Lipoprotein) Ratio Predict Major Adverse Cardiovascular Outcomes in Women With Non-Obstructive Coronary Artery Disease
J Am Heart Assoc.
Prasad M, Sara J, Widmer RJ, Lennon R, Lerman LO, Lerman A
doi: 10.1161/JAHA.118.009442.